Dr. Richard Goldberg on Pembrolizumab for Lynch Syndrome Patients

Richard Goldberg, MD
Published: Wednesday, Jul 08, 2015



Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.

A study looking at pembrolizumab in patients with colon cancer, found that the PD-1 inhibitor demonstrated a 60% response rate amongst heavily pretreated patients with Lynch syndrome.

Lynch syndrome affects about 4% of those with advanced colorectal cancer. These patients have mismatched repair and hyper-mutated tumors which can be difficult to treat, said Goldberg.

SELECTED
LANGUAGE


Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.

A study looking at pembrolizumab in patients with colon cancer, found that the PD-1 inhibitor demonstrated a 60% response rate amongst heavily pretreated patients with Lynch syndrome.

Lynch syndrome affects about 4% of those with advanced colorectal cancer. These patients have mismatched repair and hyper-mutated tumors which can be difficult to treat, said Goldberg.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x